A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
8: Co., Ltd. Rilmazafone Hydrochloriode (RZ), a prodrug of benzodiazepine derivatives, is used clinically as a sleep inducer. The pharmacokinetics of RZ in patients were studied to determine the clinical dose for patients with chronic renal failure. Five patients (2 male, 3 female, aged 44-62yr) who participated in this study were undergoing hemodialysis. They were given RZ (1mg, p. o.) one time on the day of dialysis, and 5-7 days later on the day of non-dialysis. Blood samples were collecteddoi:10.3999/jscpt.23.573 fatcat:5nfrh6e2ijc5lnofjepzmpw54m